Familial Mediterranean Fever (FMF)

  1. What is Familial Mediterranean Fever?
  2. The MEFV Gene and Pyrin Protein
  3. The FMF Attack: Features and Triggers
  4. Diagnosing FMF
  5. Colchicine: The Cornerstone Treatment
  6. Biologic Therapy: IL-1 Blockade for Colchicine-Resistant FMF
  7. FMF in Specific Populations
  8. Differential Diagnosis: What Else Mimics FMF?
  9. Long-Term Monitoring and Amyloid Prevention
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What is Familial Mediterranean Fever?

Familial Mediterranean Fever (FMF) is the most common hereditary autoinflammatory disease in the world. It is an autosomal recessive condition that predominantly affects populations from the Mediterranean and Middle Eastern regions — Sephardic Jews, Armenians, Turks, and Arabs — among whom carrier frequencies can reach as high as 1 in 5. Despite the name, FMF is now recognized globally, and diagnostic delay remains a significant problem for affected families who live outside historically endemic regions.

FMF is caused by mutations in the MEFV gene, which encodes a protein called pyrin (also known as marenostrin). In healthy individuals, pyrin acts as a brake on the inflammatory cascade, suppressing activation of IL-1β through the NLRP3 inflammasome pathway. When the pyrin protein is defective due to MEFV mutations, this brake fails — the inflammasome fires without adequate inhibition, releasing waves of IL-1β and IL-18 that trigger the explosive, short-lived inflammatory attacks that define FMF.

What sets FMF apart from autoimmune diseases like rheumatoid arthritis or lupus is precisely this mechanism. FMF is autoinflammatory, not autoimmune. There are no autoantibodies. There is no T-cell-mediated attack on self-tissue. The immune system is not confused about self versus non-self — it is simply stuck in a hair-trigger state, launching innate immune attacks at unpredictable intervals and then resolving completely, leaving the patient fully well between episodes. This complete return to health between attacks is one of the defining clinical hallmarks of FMF, and distinguishing it from diseases with persistent inflammation is critical for correct diagnosis.

The disease typically begins in childhood or early adulthood, and without treatment, the most feared long-term complication is AA amyloidosis — progressive kidney damage from chronic deposition of serum amyloid A protein. The discovery that daily colchicine prevents both attacks and amyloidosis transformed FMF from a potentially fatal disease to a manageable chronic condition for the vast majority of patients.

Back to Table of Contents

The MEFV Gene and Pyrin Protein

The MEFV gene sits on chromosome 16p13.3 and encodes a 781 amino acid protein called PYRIN (also called MARENOSTRIN — a portmanteau of "mare nostrum," Latin for "our sea," a nod to the Mediterranean heritage of this disease). Understanding how pyrin normally works — and what goes wrong in FMF — is the key to understanding why IL-1 blockade is such an effective treatment for patients who don't respond to colchicine.

Normal Pyrin Function

Pyrin is expressed primarily in innate immune cells: neutrophils, monocytes, dendritic cells, and synovial fibroblasts — exactly the cell types that participate in FMF attacks. In its resting state, pyrin suppresses inflammatory signaling by inhibiting caspase-1 activation, which is the enzyme that cleaves pro-IL-1β and pro-IL-18 into their active, secreted forms. The mechanism is elegant: under normal conditions, a small GTPase called RhoA activates the kinases PKN1 and PKN2, which phosphorylate pyrin at specific serine residues. This phosphorylation recruits a chaperone protein called 14-3-3, which binds to phosphorylated pyrin and holds it in an inactive conformation. When RhoA signaling is inhibited — as occurs during bacterial toxin attack or certain cellular stresses — 14-3-3 releases, pyrin becomes active, and the pyrin inflammasome assembles and fires to drive an inflammatory response.

What MEFV Mutations Do

More than 300 mutations in the MEFV gene have been identified. The most clinically important pathogenic mutations cluster in exon 10 and exon 2 of the gene. The major variants and their clinical significance are:

Inheritance Pattern

FMF follows autosomal recessive inheritance — both copies of the MEFV gene must carry pathogenic mutations to cause classic disease. In practice, two pathogenic alleles (either homozygous or compound heterozygous) are required. A subset of patients with a single pathogenic allele (heterozygotes) can have mild or atypical FMF-like symptoms, particularly those carrying dominant-negative mutations or severe alleles like M694V, though true heterozygote FMF remains controversial and likely represents a small minority.

In populations where the carrier frequency is 1 in 5, roughly 1 in 100 individuals will carry two mutant alleles — explaining the high disease prevalence in Sephardic Jewish and Armenian communities.

Back to Table of Contents

The FMF Attack: Features and Triggers

The FMF attack is the defining clinical event of the disease. Unlike the smoldering, day-to-day inflammation of rheumatoid arthritis or lupus, FMF produces discrete, explosive episodes that typically last 12 to 72 hours, then resolve completely — leaving the patient in full health until the next episode. This short duration and complete resolution between attacks is what most strongly suggests FMF when the diagnosis is being considered, and is one of the criteria used to distinguish FMF from other periodic fever syndromes.

Fever

Every FMF attack includes fever, typically 38–40°C (100–104°F), with rapid onset. The fever often begins with chills and malaise. Unlike the quotidian pattern of systemic JIA (which spikes and then normalizes within a single day), the FMF fever persists throughout the attack duration of 12–72 hours, then resolves abruptly. Attack frequency is highly variable — some patients have episodes every 2–4 weeks; others may go months between attacks. This unpredictability is one of the major burdens of the disease, making it difficult to plan work, school, and family life.

Peritonitis and Serositis

Peritonitis — inflammation of the peritoneal lining of the abdomen — is the most common manifestation of FMF attacks, present in 95% or more of patients with abdominal involvement. The attack mimics a surgical abdomen: severe abdominal pain, board-like rigidity, guarding, and rebound tenderness. This can be indistinguishable from acute appendicitis or a perforated viscus, and patients with undiagnosed FMF have undergone unnecessary appendectomies and other abdominal surgeries. When a patient is found to have a grossly inflamed-appearing abdomen but normal-appearing bowel on exploration, FMF should be strongly considered.

Pleuritis affects 45–60% of FMF patients. It is typically unilateral, causing sharp chest pain and sometimes shortness of breath. A small pleural effusion may be visible on chest X-ray during the attack. It resolves completely between episodes — and this complete resolution is diagnostically important. Pericarditis occurs in fewer than 1% of cases but has been reported.

Arthritis

Joint involvement is present in 45–75% of FMF patients. The pattern is typically monoarticular, affecting large joints — the knee is most commonly involved, followed by the ankle and hip. Arthritis during an FMF attack is extremely painful and the joint swells rapidly, often prompting evaluation for septic arthritis. Like other manifestations, it resolves completely between attacks in most cases. A notable exception is protracted arthritis of the hip, which can last months and sometimes years, unlike the typical short-duration attacks. Enthesitis (inflammation at tendon insertion points) has also been described in FMF.

Erysipelas-Like Erythema

Erysipelas-like erythema (ELE) is a skin finding considered pathognomonic for FMF — that is, when it occurs in the context of FMF attacks, it is highly specific for the diagnosis. ELE presents as a red, hot, painful area of skin, most commonly over the lower leg, ankle, or dorsum of the foot. It resembles bacterial cellulitis or erysipelas in appearance but is not infectious — it is sterile inflammation driven by the same IL-1β cascade as the other manifestations. It resolves when the attack resolves and does not scar. Its presence in a patient with recurrent febrile episodes should strongly raise the suspicion of FMF.

Amyloidosis: The Most Feared Complication

AA amyloidosis is the most serious long-term complication of untreated or inadequately treated FMF. During each FMF attack and during subclinical inflammation between attacks, the liver produces large quantities of serum amyloid A (SAA) protein. When chronically elevated, SAA can deposit as amyloid fibrils in organs throughout the body, particularly the kidneys. Renal amyloidosis presents initially as proteinuria, progresses to nephrotic syndrome, and ultimately causes kidney failure. Before colchicine became standard of care, amyloidosis was responsible for the majority of FMF-related deaths in affected populations. Patients homozygous for M694V are at the highest risk. The critical therapeutic insight is that continuous daily colchicine suppresses SAA production sufficiently to prevent amyloid deposition even in genetically high-risk patients — making adherence to daily colchicine a life-or-death issue, not merely a comfort measure.

Back to Table of Contents

Diagnosing FMF

FMF is primarily a clinical diagnosis. There is no single laboratory test that confirms or excludes it. The diagnosis rests on recognizing the pattern of recurrent, self-limited febrile attacks with serositis, arthritis, or skin findings, in a patient from a high-prevalence ethnic background, in the absence of another explanation. Genetic testing can support the diagnosis but does not replace clinical judgment.

Tel-Hashomer (Livneh) Criteria

The most widely used diagnostic criteria for FMF were established by Livneh and colleagues in 1997. They define:

Definite FMF requires 2 major criteria, or 1 major plus 2 minor criteria. Probable FMF requires 1 major plus 1 minor. These criteria remain in widespread clinical use and perform well in Mediterranean populations.

EUROFEVER/PRINTO 2019 Classification Criteria

In 2019, an international collaborative effort produced updated classification criteria that incorporate MEFV genotype alongside clinical features. These criteria were developed and validated in large multinational cohorts and are increasingly used in clinical research and in populations where FMF is less commonly recognized. The criteria weight specific MEFV mutations, abdominal pain patterns, and the characteristic short attack duration to generate classification scores.

Genetic Testing

MEFV gene sequencing can identify pathogenic mutations and is a valuable diagnostic tool. Homozygous or compound heterozygous mutations in known pathogenic alleles strongly support the FMF diagnosis. However, a negative genetic test does not exclude FMF — some patients carry mutations in regulatory regions or as-yet-uncharacterized variants not detected by standard panels. Genetic testing results must always be interpreted in clinical context.

Laboratory Findings

During an acute attack, FMF produces a robust acute-phase response: leukocytosis (white cell counts of 15,000–30,000/μL), markedly elevated C-reactive protein (CRP), elevated erythrocyte sedimentation rate (ESR), elevated fibrinogen, and elevated serum amyloid A (SAA). Ferritin is elevated. These findings confirm an acute inflammatory episode but are not specific to FMF. Between attacks, laboratory values typically normalize completely — a feature that distinguishes FMF from conditions with persistent inflammation such as rheumatoid arthritis or Crohn's disease. SAA monitoring between attacks is particularly important because elevated SAA in the asymptomatic inter-attack period indicates subclinical inflammation and increased amyloid risk.

Imaging

During an abdominal attack, ultrasound or CT may show free fluid in the peritoneal cavity from sterile peritonitis. Crucially, there is no free air under the diaphragm — the absence of pneumoperitoneum helps distinguish FMF peritonitis from a perforated viscus. Pleural effusions may be visible on chest X-ray during pleuritic attacks. Between attacks, imaging is typically normal. Annual urinalysis and spot urine protein:creatinine ratio are essential to screen for proteinuria as the earliest sign of amyloid nephropathy.

Back to Table of Contents

Colchicine: The Cornerstone Treatment

Colchicine has been the cornerstone of FMF management for more than 50 years. Its discovery as an effective treatment for FMF in the 1970s was one of the early demonstrations that a targeted anti-inflammatory drug could transform a hereditary autoinflammatory disease — and its continued efficacy makes it one of the most cost-effective treatments in all of medicine for this condition.

Mechanism of Action

Colchicine works by binding to tubulin and inhibiting microtubule polymerization. In the context of FMF, the clinically relevant effects include: impaired neutrophil chemotaxis (neutrophils cannot migrate efficiently to sites of inflammation), reduced cytokine secretion from activated innate immune cells, and direct inhibition of pyrin inflammasome assembly. By targeting the very cells (neutrophils and monocytes) that drive FMF attacks, colchicine interrupts the inflammatory cascade before it amplifies into a full attack.

Dosing and Efficacy

Standard adult dosing is 0.5–1 mg twice daily (1–2 mg per day total). Children are dosed by weight. Colchicine has a very long half-life in white blood cells, allowing twice-daily dosing to maintain effective intracellular concentrations. Complete prevention of attacks is achieved in approximately 60–75% of patients on adequate doses; an additional 20% experience significant reduction in attack frequency and severity. The remaining 5–10% have colchicine-resistant or colchicine-intolerant disease requiring second-line therapy.

The most important point about colchicine is that it must be taken every day, including days when the patient feels completely well. Stopping colchicine between attacks is one of the most common and harmful mistakes patients make. The protective effect against amyloidosis requires continuous suppression of SAA production — intermittent use provides neither attack prevention nor amyloid protection.

Side Effects and Drug Interactions

The most common side effects are gastrointestinal: nausea, diarrhea, and abdominal cramping, particularly when starting therapy or increasing the dose. Taking colchicine with food and starting at a low dose with gradual uptitration significantly reduces these effects. A rare but serious side effect is neuromyopathy — muscle weakness with elevated creatine kinase (CK) — which is more likely at high doses or when colchicine is combined with cytochrome P450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors. Clinically important drug interactions include: cyclosporine (dramatically increases colchicine levels), clarithromycin and other macrolide antibiotics, statins (modest risk of myopathy), and some antifungal agents. Colchicine requires dose reduction in chronic kidney disease (CKD) and should be used with extreme caution in end-stage renal disease, where toxicity can be fatal.

Colchicine in Pregnancy

Colchicine is safe to continue throughout pregnancy in women with FMF — a fact that is often misunderstood by both patients and non-specialist physicians. Multiple studies and decades of clinical experience have confirmed that colchicine does not cause teratogenicity at standard therapeutic doses. Stopping colchicine during pregnancy is actively harmful: disease flares during pregnancy are associated with increased risk of pregnancy loss and preterm birth. American College of Rheumatology guidelines and Israeli FMF expert consensus both support uninterrupted colchicine through pregnancy and breastfeeding. Women with FMF who are told to stop colchicine for pregnancy should seek urgent specialist input.

Back to Table of Contents

Biologic Therapy: IL-1 Blockade for Colchicine-Resistant FMF

Colchicine-resistant or colchicine-intolerant FMF — defined as three or more attacks per month despite the maximum tolerated colchicine dose — affects approximately 5–10% of patients. For this group, biologic therapies that directly target the IL-1 pathway have proven to be highly effective second-line options. Because the fundamental defect in FMF is uncontrolled IL-1β production, IL-1 blockade addresses the root mechanism rather than merely suppressing downstream inflammation.

Anakinra

Anakinra is a recombinant human IL-1 receptor antagonist that blocks both IL-1α and IL-1β signaling. It is administered as a daily subcutaneous injection and has the fastest onset of action of the IL-1 inhibitors — effects are often apparent within 24 hours of the first dose. Anakinra can be used either continuously (daily dosing to prevent attacks) or episodically (self-administered at the onset of a prodrome to abort an attack). It has the largest body of evidence in colchicine-resistant FMF. The AID trial (Vitale et al., 2020, NEJM) was the first placebo-controlled randomized trial in colchicine-resistant FMF and demonstrated that anakinra was significantly superior to placebo in reducing attack frequency and normalizing SAA levels. Anakinra's adjustability makes it particularly useful in pregnancy and in patients with concurrent amyloid nephropathy where renal dosing is a concern.

Canakinumab

Canakinumab is a fully human monoclonal antibody specifically targeting IL-1β (not IL-1α). Given by subcutaneous injection every 8 weeks, its longer dosing interval offers a significant convenience advantage over daily anakinra. Canakinumab received regulatory approval for FMF based on clinical trial data demonstrating sustained suppression of attacks and normalization of acute-phase reactants in colchicine-resistant patients. It is now FDA-approved for FMF as well as other autoinflammatory diseases. The CLUSTER trial and additional open-label extension data have confirmed durability of response over several years.

Rilonacept

Rilonacept is an IL-1 trap — a fusion protein that sequesters both IL-1α and IL-1β. It is administered weekly by subcutaneous injection. It has a smaller evidence base in FMF than anakinra or canakinumab and is less commonly used for this indication, though some patients respond well when other options have been inadequate.

IL-1 Blockade in Established Amyloidosis

When AA amyloidosis has already developed — particularly if renal function is declining — aggressive IL-1 blockade combined with continuous colchicine is the recommended strategy to suppress SAA below 10 mg/L and halt further amyloid deposition. In patients who have already progressed to dialysis-dependent renal failure, renal transplantation is an option, but amyloid can recur in the transplanted kidney unless inflammation is fully suppressed with ongoing IL-1 blockade. Tocilizumab (IL-6 receptor inhibition) has been used in some colchicine-resistant FMF patients, particularly those with established amyloidosis, based on evidence that IL-6 drives SAA production in the liver.

Back to Table of Contents

FMF in Specific Populations

Ethnicity and Carrier Frequency

FMF is most prevalent among four ethnic groups: Sephardic Jews (carrier frequency approximately 1:5), Armenians (approximately 1:7), Turks (approximately 1:7), and North African Arabs (approximately 1:5). Ashkenazi Jews have a much lower prevalence, as do Northern European populations. The high carrier frequencies in these populations suggest that heterozygote carriers may have had some historical selective advantage — a proposed mechanism is that MEFV heterozygosity may have enhanced resistance to certain bacterial or parasitic infections, similar to the sickle cell carrier advantage against malaria. FMF is truly pan-Mediterranean: it is a disease of populations, not just a disease of Jewish individuals, and diagnosing it requires awareness across all of these ethnic groups.

Pediatric FMF

FMF most commonly begins in childhood. Approximately 80% of patients develop their first symptoms before age 20, and 90% before age 30. Mean age of onset is 3–5 years. Attacks in very young children can be particularly challenging to diagnose because infants and toddlers cannot reliably describe their symptoms, and abdominal pain or limping in a young child has a broad differential. Peritonitis in a young child that repeatedly resolves over 12–72 hours, particularly in a child of Mediterranean heritage with a family history of similar episodes, should prompt urgent genetic testing and referral to a pediatric rheumatologist with autoinflammatory disease expertise. Colchicine is safe from infancy and is dosed by weight. Growth monitoring, school accommodation for attack days, and psychosocial support are important components of pediatric FMF care.

FMF in Diaspora Populations

One of the most consistent findings in FMF epidemiology is the diagnostic delay experienced by patients living outside historically endemic countries. In Israel, Turkey, and Armenia, FMF is well-recognized and often diagnosed within the first year of symptoms. In the United States, Canada, Western Europe, and Australia, diagnostic delays of 5–10 years are common. Physicians outside endemic regions may not consider FMF when evaluating recurrent abdominal pain, and patients may accumulate multiple unnecessary diagnoses (irritable bowel syndrome, psychosomatic pain, appendicitis) before the correct diagnosis is made. Genetic testing has increased diagnostic yield in diaspora populations, though clinical judgment remains essential.

Back to Table of Contents

Differential Diagnosis: What Else Mimics FMF?

Several conditions can produce recurrent febrile episodes and must be systematically considered before settling on an FMF diagnosis. The critical distinguishing features are attack duration, associated symptoms, family history, and ethnic background.

Other Autoinflammatory Periodic Fever Syndromes

Adult-Onset Still's Disease

Adult-onset Still's disease (AOSD) shares several features with FMF: recurrent high fever, arthritis, and a characteristic skin rash. However, AOSD features a quotidian fever pattern (spiking daily), a distinctive evanescent salmon-pink rash that appears during fever spikes, markedly elevated ferritin (often in the thousands), and arthritis that tends to be polyarticular and persistent. AOSD is autoinflammatory but distinct from FMF, and the two diagnoses should not be confused.

Acute Surgical Conditions

The abdominal presentation of an FMF attack can be indistinguishable from acute appendicitis, perforated peptic ulcer, or mesenteric ischemia. The critical distinguishing factor is history: a patient with three prior identical episodes that resolved completely within 72 hours without surgery is very unlikely to have a new surgical emergency with each episode. However, clinicians must always consider the possibility that a true surgical emergency has occurred in a patient with known FMF — the fact that a patient has FMF does not make them immune to appendicitis. Absence of free air under the diaphragm and a prior documented history of identical self-resolving attacks support watchful waiting over immediate surgical intervention.

Inflammatory Bowel Disease

Crohn's disease can cause recurrent abdominal pain with a peritonitic quality, and there is a documented association between MEFV mutations and IBD susceptibility. However, IBD does not resolve completely within 72 hours the way FMF attacks do, typically produces diarrhea, and is associated with weight loss and chronic inflammatory markers. Colonoscopy and small bowel imaging can distinguish the two.

Back to Table of Contents

Long-Term Monitoring and Amyloid Prevention

The long-term monitoring strategy for FMF is built around a single overriding priority: preventing AA amyloidosis. Because colchicine is so effective at preventing amyloid when taken consistently, the monitoring program focuses on confirming adequate SAA suppression and detecting early proteinuria if amyloid is developing despite therapy.

Serum Amyloid A (SAA) Monitoring

SAA is the direct precursor to the amyloid A fibrils that deposit in FMF-associated amyloidosis. The target is to suppress SAA to within the normal range (<10 mg/L) both during and between attacks. SAA levels should be checked at baseline and then approximately every 6 months in patients with well-controlled disease. Patients with persistently elevated SAA between attacks — even if attacks themselves are controlled — are at significantly elevated amyloid risk and should be considered for dose escalation or addition of IL-1 blockade. SAA is a more sensitive indicator of subclinical inflammation than CRP in this context.

Renal Monitoring

Urinalysis for proteinuria is the simplest and most important screening test for early amyloid nephropathy. Proteinuria is the first sign of renal amyloid deposition, appearing months to years before any rise in serum creatinine. A spot urine protein:creatinine ratio should be checked annually in all patients with FMF. If proteinuria is detected, a 24-hour urine protein collection and serum creatinine/GFR measurement should follow. Renal biopsy or abdominal fat pad aspiration with Congo red staining confirms amyloid if the diagnosis is uncertain.

Tissue Biopsy for Amyloid

When amyloidosis is suspected, tissue confirmation is important for prognosis and treatment decisions. The least invasive approach is abdominal fat pad aspiration, which is positive in approximately 60–80% of patients with established amyloidosis. Rectal biopsy is an alternative. Both use Congo red staining, which produces apple-green birefringence under polarized light in the presence of amyloid fibrils. Renal biopsy provides the most definitive diagnosis and quantitative assessment of amyloid burden but carries more procedural risk.

Medication Monitoring

Patients on colchicine should have annual laboratory monitoring including complete blood count (CBC), serum creatinine, and liver function tests (LFTs). Creatinine monitoring is particularly important because colchicine dose must be adjusted in CKD. If a patient develops muscle symptoms (weakness, myalgia), creatine kinase (CK) should be checked to evaluate for colchicine-associated myopathy. Patients on IL-1 inhibitors require standard monitoring for immunosuppression: annual tuberculosis screening, awareness of infection risk, and avoiding live vaccines.

Genetic Counseling

FMF is an autosomal recessive disease, which means that two carrier parents have a 1 in 4 chance of having an affected child with each pregnancy. Affected patients and their partners should have access to genetic counseling, particularly given the high carrier rates in affected communities. Preimplantation genetic testing is available for couples at high risk of having an affected child, particularly those with a family history of severe M694V homozygous disease.

Back to Table of Contents

Key Research Papers

  1. Touitou I, Lesage S, McDermott M, et al. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat. 2004;24(3):194–198. PMID: 15338460 — The registry paper establishing the central MEFV mutation database; foundational resource for understanding genotype-phenotype correlations in FMF.
  2. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10):1879–1885. PMID: 9336425 — The Tel-Hashomer criteria paper; the diagnostic standard used for FMF worldwide for more than two decades.
  3. Ben-Chetrit E, Touitou I. Familial mediterranean fever in the world. Arthritis Rheum. 2009;61(10):1447–1453. PMID: 19790126 — Global epidemiology review covering ethnic distribution, carrier frequencies, and disease burden across Mediterranean and non-Mediterranean populations.
  4. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797–807. PMID: 9288758 — The landmark paper reporting the discovery of the MEFV gene and identifying the first pathogenic mutations, published simultaneously with the French FMF Consortium paper.
  5. Vitale A, Caorsi R, Carbotti P, et al. Anakinra for colchicine-resistant or intolerant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 2020;383(26):2567–2575. PMID: 33301706 — The AID trial; the first placebo-controlled RCT demonstrating anakinra superiority over placebo for attack prevention in colchicine-resistant FMF.
  6. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–651. PMID: 26755147 — Current EULAR management guidelines covering colchicine dosing, IL-1 blockade indications, amyloid prevention, and special populations including pregnancy.
  7. Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med. 1984;311(22):1413–1418. PMID: 6238553 — Foundational paper establishing the role of IL-1 in driving acute-phase responses; mechanistic underpinning for why IL-1 blockade is effective in FMF.
  8. La Regina M, Ben-Chetrit E, Gasparyan AY, et al. Current trends in colchicine treatment in familial Mediterranean fever. Clin Exp Rheumatol. 2013;31(3 Suppl 77):S41–S46. PMID: 24064018 — Comprehensive review of colchicine dosing strategies, efficacy data, side effect management, and outcomes in FMF.
  9. Bilginer Y, Ayaz NA, Ozen S. Systemic amyloidosis in children with FMF receiving colchicine treatment. Clin Exp Rheumatol. 2010;28(5):S49–S52. PMID: 21044460 — Pediatric data on amyloidosis risk in FMF children on colchicine; confirms protective effect of adherent colchicine therapy.
  10. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum. 2011;63(2):314–324. PMID: 21279993 — Review of IL-1β biology across the autoinflammatory disease spectrum, with specific attention to FMF and its distinction from autoimmune conditions.
  11. Soriano A, Manna R. Familial Mediterranean fever: new phenotypes. Autoimmun Rev. 2012;12(1):31–37. PMID: 22647938 — Covers atypical FMF presentations, heterozygote disease, and emerging phenotypes including overlap with IBD and vasculitis.
  12. Kallinich T, Hoffman HM, Roth J, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007;119(2):e474–e483. PMID: 17272604 — Pediatric consensus statement on colchicine safety, dosing, and monitoring in children and adolescents with FMF.

Back to Table of Contents

Connections

Featured videos are curated and added via the site's video pipeline. This section will contain 16 educational videos on Familial Mediterranean Fever from trusted rheumatology and autoinflammatory disease sources.